Universidad de Burgos RIUBU Principal Default Universidad de Burgos RIUBU Principal Default
  • español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
Universidad de Burgos RIUBU Principal Default
  • Ayuda
  • Contact Us
  • Send Feedback
  • Acceso abierto
    • Archivar en RIUBU
    • Acuerdos editoriales para la publicación en acceso abierto
    • Controla tus derechos, facilita el acceso abierto
    • Sobre el acceso abierto y la UBU
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of RIUBUCommunities and CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics
    View Item 
    •   RIUBU Home
    • E-Prints
    • Departamentos
    • Departamento de Biotecnología y Ciencia de los Alimentos
    • Área de Bioquímica y Biología Molecular
    • Artículos Bioquímica y Biología Molecular
    • View Item
    •   RIUBU Home
    • E-Prints
    • Departamentos
    • Departamento de Biotecnología y Ciencia de los Alimentos
    • Área de Bioquímica y Biología Molecular
    • Artículos Bioquímica y Biología Molecular
    • View Item

    Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10259.4/2515

    Título
    Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
    Autor
    Izquierdo, María Jesús .
    Cavia Saiz, MónicaUBU authority
    Muñiz Rodríguez, PilarUBU authority
    Francisco, Angel LM de .
    Arias, Manuel .
    Santos, Javier .
    Abaigar, Pedro .
    Publicado en
    BMC Nephrology, 2012, 13, 159
    Editorial
    BioMed Central
    Fecha de publicación
    2012-11
    ISSN
    1471-2369
    Abstract
    Background: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional antioxidant capacity of paricalcitol in a clinical setting. Methods: The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups, indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase, reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained. Results: Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased. Conclusions: In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress and inflammation, two well known factors leading to cardiovascular damage
     
    Background: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional antioxidant capacity of paricalcitol in a clinical setting. Methods: The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups, indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase, reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained. Results: Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased. Conclusions: In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress and inflammation, two well known factors leading to cardiovascular damage.
    Palabras clave
    Oxidative Stress
    Immunomodulation
    Receptors
    Calcitrio
    Paricalcitol
    19-nor-1alpha
    25-dihydroxyvitamin D2
    Materia
    Bioquímica
    Biochemistry
    Biología molecular
    Molecular biology
    URI
    http://hdl.handle.net/10259.4/2515
    Versión del editor
    https://doi.org/10.1186/1471-2369-13-159
    Collections
    • Artículos Bioquímica y Biología Molecular
    Files in this item
    Nombre:
    1471-2369_13_159.pdf
    Tamaño:
    187.3Kb
    Formato:
    Adobe PDF
    Thumbnail
    FilesOpen

    Compartir

    Export

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • oai_openaire
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Academic Search
    Show full item record